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38 Thong Where's the block ?
Twenty five years have now passed since the first implantation of a cardiac pacemaker in man.' More than 500 000 patients have had units implanted and no dispute exists about the safety and efficacy of therapeutic pacing for symptomatic bradycardia. So the recent publication of the quadrennial world survey of cardiac pacing makes depressing reading for British cardiologists and should concern the British public.2 The proportion of the population fitted with pacemakers in Britain is only one fifth of that in the major developed countries; it is less than half the average in western Europe and only slightly greater than the average in eastern Europe. Only Greece, Spain, and Portugal in western Europe provide a poorer service to the community in terms of pacing, and historically Britain now lags some 14 years behind the United States in rates of implantation.
These data demand both questioning and interpretation. The figures themselves are probably correct. The world survey of cardiac pacing has been carefully built up over malny years from international contacts, and many countries (of which Britain was the first) now operate complex interactive computerised data bases which link the pacing centres. The nature of the procedure and the availability of manufacturers' sales figures for cross checking make pacing practice an ideal subject for accurate medical audit.
By nature British medical practice is conservative, and it might be argued that the disparity with other countries is due to their unnecessary implantation of large numbers of pacemakers. If the data are broken down to represent implantation rates for "hard" (syncope) and "soft" (heart failure/cerebral dysfunction) indications the results do not not show much change. For the "hard" indications the British rate is 31% of the United States equivalent, and only Portugal in western Europe has a lower implant rate. The numbers of pacemakers implanted for "soft" indications are three times greater in the United States than in Britain, but these account for only 18% of the overall number in the United States. Nor can variation in the distribution of the population by age and sex account for the differences: Britain has a relatively high proportion of people in the older age groups, in whom heart block is more prevalent.3 No relation exists between implant rate and physician fee for service in North America and western Europe, and remarkably there is an inverse relation with the direct cost of a pacemaker. Britain is a prestigious, highly competitive, and cost conscious market for pacemaker manufacturers: for equivalent devices prices in the United States are 300%0 higher and in Europe 150% higher than in Britain. This is all the more surprising since there is no British owned manufacturer and in theory no external control of buying policy is imposed on British cardiologists. No evidence exists that direct costs influence implant rates in Britain, though the choice of device is subject to intense restriction on regional costs (P Sleight, personal communication). With the reduction in worldwide rate of growth of the pacemaker market Britain seems unlikely to continue to benefit from low prices at the expense of other countries.
If the figures are correct and the problem does not relate to economic factors then the system of medical practice itself must be examined. Cardiology in Britain is highly centralised. The 62 pacing centres on average implant more than 100 generators each year, and 87% have full specialised cardiovascular services-compared with figures in the United States of 35 generators a centre and about 20% with full services.
In terms of the proportion of complex pacing systems implanted then Britain (900) tends to use more advanced devices than the major European countries (typically 3-40 %); the rate in Britain is comparable with that in the United States (11 %) on 1981 figures. Indeed, many of the more recent conceptual advances in pacing have arisen in Britain. [4] [5] [6] [7] This centralisation of services gives a clue to an important difference between practice in Britain and that in other countries. Each pacing centre in the United States serves on average a population of 67 000. No major west European country has centres serving more than 500 000, and only in Portugal does a centre have to cope with more than 1 million. In Britain each centre services a population of900 000. There is a statisticallyhighlysignificant correlation (r= -0-68; p < 0 001) between the population served by a pacing centre and implant rate in the North American and European countries. Assessed in terms of efficiency (where a country has a high implant rate concentrated in a limited number of facilities) then East Germany, Austria, and France lead the rankings.
The low implant rate in Britain should not be a natural consequence of the concentration of cardiological skills. The facilities exist, and, though struggling, do not appear to be restricted by cost. The bald fact seems to be that patients are not being referred appropriately for consideration of pacing.
In England in 1982 there were only 107 adult cardiologists in post, each therefore being responsible for a population of 387 000 adults. Even when one adds the 111 physicians de facto practising cardiology (defined as more than 40% of their workload) then each cardiovascular physician appears to be responsible for 190 000 adults. Equally remarkable is the fact that 55 of the 206 health districts, serving a population in excess of 10 million, appear to have no physician with special training in the management of cardiovascular disease.8 Though the overall number of doctors per head of population is moderately less than in North America and western Europe (7900 of the United States figure),3 the number of cardiologists in Britain is very low, at roughly one eleventh of that recommended for the United States. 9 I suspect that pacing practice, being well documented and easy to audit, highlights a more general problem of cardiovascular care in the British population. Such underprovision of services is likely to influence the death rate from coronary disease in this country, which is not showing the same rate of decline as that seen in the United States.10
The problem is not primarily one for our political and economic masters, though the solution will require their support. The profession itself must take responsibility for the training and deployment of medical skills in both general practitioner and hospital doctors, and must be prepared to adapt career structures and specialist distribution according to need. Audit of pacing practice leads to the inescapable conclusion that the British patient with cardiovascular disease is not well served by the medical profession.
A F RICKARDS Death in the street When a man or woman collapses in the street, or is injured in a road accident, or is pulled unconscious from water his or her chances of survival depend on chance. If the victim is lucky the onlookers will include someone trained in cardiopulmonary resuscitation; but without luck he may die. Asphyxia is an unforgiving enemy. The visitor from Britain to Rotterdam will see stickers in the windows of many shops announcing that the staff have been trained in resuscitation. Australian television shows regular commercials encouraging people to attend training courses. All the Scandinavian countries have established training schemes, some of which extend to all schoolchildren.
Here in Britain-as became plain last week at a symposium at the Royal Society of Medicine-we have the familiar pattern of indifference and apathy at the Department of Health, a few committed medical enthusiasts, good intentions in the voluntary associations that provide first aid, and no single body with the duty-let alone the intention-of coordinating the efforts being made by these groups to organise a national training scheme.
Nearly 20 years have passed since Pantridge and his colleagues began their work in Belfast with the use of coronary ambulances to cut mortality from heart disease.' Chamberlain's efforts in Brighton have shown that education of the public not only saves lives in the street and in the home but also-and possibly this is more important in terms of lives saved-leads to many more patients reaching hospital within an hour of the onset of symptoms of myocardial infarction.2 Yet the sceptics remain unconvinced of the value of training ambulance staff and equipping vehicles with defibrillators. This scepticism provided ammunition for the Department of Health when it decided in 1976 that there was "no firm evidence" that the use of coronary ambulances saved lives.3 A recent survey found only nine ambulance based resuscitation schemes in England.4
With so few coronary ambulances, is there any point in encouraging Britons to acquire the basic skills of cardiopulmonary resuscitation? Will they find themselves kneeling in the rain, waiting 20 minutes for an ambulance that eventually arrives with untrained staff and no defibrillator? That is, in current jargon, a worst case scenario. A mass education campaign would certainly save lives from asphyxia associated with drowning, electrocution, and trauma, and would-if the Brighton experience is a guide-cut mortality from myocardial infarction even in cities without coronary ambulances.
The Resuscitation Council-a small, informal medical advisory panel-has just published a booklet describing the necessary lifesaving techniques in simple words.5 Sadly, its
